NASDAQ:CLSD - Clearside Biomedical Stock Price, Forecast & News

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical Inc (NASDAQ:CLSD) announced its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.17) EPS for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.01. The firm earned $0.14 million during the quarter, compared to analyst estimates of $0.05 million. Clearside Biomedical had a negative return on equity of 316.25% and a negative net margin of 18,893.49%. View Clearside Biomedical's Earnings History.

Clearside Biomedical is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Clearside Biomedical.

4 brokers have issued 12-month price objectives for Clearside Biomedical's shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Clearside Biomedical's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 75.4% from the stock's current price. View Analyst Price Targets for Clearside Biomedical.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clearside Biomedical.

Press coverage about CLSD stock has trended very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clearside Biomedical earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Clearside Biomedical.

Clearside Biomedical saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,510,000 shares, an increase of 112.5% from the December 31st total of 710,700 shares. Based on an average daily volume of 1,080,000 shares, the short-interest ratio is presently 1.4 days. Approximately 4.7% of the shares of the stock are short sold. View Clearside Biomedical's Current Options Chain.

Some companies that are related to Clearside Biomedical include BioSpecifics Technologies (BSTC), Beyondspring (BYSI), Innate Pharma (IPHYF), Progenics Pharmaceuticals (PGNX), AnaptysBio (ANAB), Organogenesis (ORGO), Mallinckrodt (MNK), Cue Biopharma (CUE), Mersana Therapeutics (MRSN), Merus (MRUS), Aptorum Group (APM), DURECT (DRRX), Avedro (AVDR), Kindred Biosciences (KIN) and Dynavax Technologies (DVAX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), Zeltiq Aesthetics (ZLTQ), Immunomedics (IMMU), Nabriva Therapeutics (NBRV), Proteostasis Therapeutics (PTI), Agile Therapeutics (AGRX), TG Therapeutics (TGTX) and Amarin (AMRN).

(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical's stock is owned by many different of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.62%), Oxford Asset Management LLP (0.30%), Renaissance Technologies LLC (0.20%), Signaturefd LLC (0.13%), Virtu Financial LLC (0.12%) and Wedbush Securities Inc. (0.09%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Clay Thorp, Daniel H White, George M Lasezkay and Gerald D Cagle. View Institutional Ownership Trends for Clearside Biomedical.

CLSD stock was sold by a variety of institutional investors in the last quarter, including Signaturefd LLC, Wedbush Securities Inc. and UBS Group AG. View Insider Buying and Selling for Clearside Biomedical.

CLSD stock was bought by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Renaissance Technologies LLC, Virtu Financial LLC, Geode Capital Management LLC, Fred Alger Management LLC, Integrated Advisors Network LLC, Donald L. Hagan LLC and Game Plan Financial Advisors LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Clay Thorp, Daniel H White, George M Lasezkay and Gerald D Cagle. View Insider Buying and Selling for Clearside Biomedical.

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLSD stock can currently be purchased for approximately $2.57.

Clearside Biomedical has a market capitalization of $113.92 million and generates $30,000.00 in revenue each year. The company earns $-82,820,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.View Additional Information About Clearside Biomedical.

The official website for Clearside Biomedical is http://www.clearsidebio.com/.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]